Abeona Therapeutics (NASDAQ:ABEO) on Wednesday reported financial results for the full year ended December 31, 2025, and provided operational updates centered on the commercial launch of its lead gene therapy ZEVASKYN.
The company generated total revenue of $5.8 million for the year, while recording a net gain of $152.4 million from the sale of a Rare Pediatric Disease Priority Review Voucher.
Cash and short-term investments stood at $191.4 million at year-end.
Meanwhile, ZEVASKYN, approved by the U.S. Food and Drug Administration for the treatment of recessive dystrophic epidermolysis bullosa, began its commercial launch in the fourth quarter of 2025.
The first commercial patient was treated in December, marking the transition from clinical development to revenue-generating operations.
Treatments and patient biopsies resumed in early 2026 following a temporary manufacturing shutdown.
Elsewhere, the company noted rising selling, general and administrative expenses associated with commercialization activities, as well as $1.5 million in cost of sales related to initial production batches.